# Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone

> **NCT02634463** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 81 (actual)

## Conditions studied

- Immunoassay
- Antipsychotic

## Interventions

- **DRUG:** Aripiprazole
- **OTHER:** Olanzapine
- **DRUG:** Paliperidone
- **DRUG:** Risperidone

## Key facts

- **NCT ID:** NCT02634463
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-09
- **Primary completion:** 2016-11-09
- **Final completion:** 2016-11-09
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2025-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02634463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02634463, "Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02634463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*